\u0130leri evre over kanserinde birinci basamak kemoterapiye bevacizumab eklenmesinin ger\u00e7ek d\u00fcnya sonu\u00e7lar\u0131n\u0131 inceleyen kapsaml\u0131 elektronik sa\u011fl\u0131k kay\u0131tlar\u0131 veritaban\u0131na dayanan yeni bir ara\u015ft\u0131rma, bu tedavinin faydalar\u0131n\u0131n s\u0131n\u0131rl\u0131 oldu\u011funu ve \u00f6zellikle y\u00fcksek riskli hasta alt gruplar\u0131yla s\u0131n\u0131rl\u0131 kald\u0131\u011f\u0131n\u0131 ortaya koydu. American Cancer Society\u2019nin sayg\u0131n dergisi CANCER\u2019da yay\u0131mlanan \u00e7al\u0131\u015fmada, bevacizumab\u0131n eklenmesinin sa\u011fkal\u0131mda genel hastalar aras\u0131nda anlaml\u0131 bir uzama sa\u011flamad\u0131\u011f\u0131; ancak cerrahi sonras\u0131 rezid\u00fcel t\u00fcm\u00f6r hacmi ve hastal\u0131\u011f\u0131n yayg\u0131nl\u0131\u011f\u0131 gibi y\u00fcksek risk fakt\u00f6rlerine sahip hastalarda zamana ba\u011fl\u0131 olarak iyile\u015fme g\u00f6zlendi\u011fi belirtildi. Hastalar\u0131n risk profillerine g\u00f6re tedavi stratejilerinin ki\u015fiselle\u015ftirilmesinin tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131rmada ve gereksiz ila\u00e7 kullan\u0131m\u0131 ile olumsuz etkileri azaltmada \u00f6nemli oldu\u011fu vurguland\u0131. <\/p>\n
Bevacizumab, t\u00fcm\u00f6r\u00fcn kanlanmas\u0131n\u0131 art\u0131ran VEGF-A molek\u00fcl\u00fcn\u00fc hedef alan monoklonal antikor olarak, t\u00fcm\u00f6r geli\u015fimini sa\u011flayan yeni kan damarlar\u0131n\u0131n olu\u015fumunu engeller. \u00c7e\u015fitli kanserlerde kullan\u0131m onay\u0131 alan bevacizumab\u0131n over kanserindeki rol\u00fc son y\u0131llarda yo\u011fun \u015fekilde mercek alt\u0131na al\u0131nd\u0131. Klinik deneylerde, t\u00fcm hastalar i\u00e7in genel sa\u011fkal\u0131m\u0131 anlaml\u0131 \u015fekilde uzatmad\u0131\u011f\u0131 g\u00f6r\u00fclse de, ileri evre hastal\u0131k ve cerrahi sonras\u0131 rezid\u00fcel hastal\u0131\u011f\u0131 bulunan y\u00fcksek riskli hastalarda belirli bir sa\u011fkal\u0131m avantaj\u0131 oldu\u011fu g\u00f6sterilmi\u015fti. Ancak uzun d\u00f6nem takiplerde bu avantaj t\u00fcm hasta pop\u00fclasyonu i\u00e7in netle\u015fmedi. <\/p>\n
Ger\u00e7ek d\u00fcnya ko\u015fullar\u0131nda bu klinik sonu\u00e7lar\u0131n do\u011frulu\u011funu test etmek ve uygulamadaki etkinli\u011fini de\u011ferlendirmek amac\u0131yla ara\u015ft\u0131rmac\u0131lar, 2017 ile 2023 y\u0131llar\u0131 aras\u0131nda ileri evre (evre III ve IV) over kanserli 1.752 kad\u0131n\u0131n elektronik sa\u011fl\u0131k kay\u0131tlar\u0131n\u0131 geriye d\u00f6n\u00fck olarak analiz etti. Bu hastalar, ilk basamak kemoterapi tedavilerine bevacizumab eklenerek veya kemoterapi tek ba\u015f\u0131na uygulanarak tedavi edilmi\u015f olup, ortanca 18 ayl\u0131k takip s\u00fcresi ile tedavi etkinli\u011fi detayl\u0131 \u015fekilde incelendi. <\/p>\n
Hastalar, prognoz fakt\u00f6rleri temelinde y\u00fcksek ve d\u00fc\u015f\u00fck risk gruplar\u0131na ayr\u0131ld\u0131. Bu sayede bevacizumab\u0131n etkileri \u00f6zellikle y\u00fcksek risk hastalar i\u00e7in sorguland\u0131. Ara\u015ft\u0131rmada, tedavi etkinli\u011finin dayanaklar\u0131ndan biri olarak kabul edilen, hastal\u0131\u011f\u0131n ilerlemesi veya tedavi ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 sonras\u0131 yeni tedaviye ba\u015flama s\u00fcresini g\u00f6steren \u201cTTNT (next treatment\u2019a kadar ge\u00e7en s\u00fcre)\u201d parametresinin, bevacizumab eklenen grupta belirgin \u015fekilde uzad\u0131\u011f\u0131 g\u00f6zlendi. Bevacizumab ile tedavi edilenlerde TTNT medyan\u0131 13,6 ay iken, kemoterapi tek ba\u015f\u0131na alanlarda 11,7 ay olarak tespit edildi. Bu durum hastal\u0131\u011f\u0131n ilerleyi\u015finin belirli bir s\u00fcre engellendi\u011fini ve klinik anlamda gecikme sa\u011fland\u0131\u011f\u0131n\u0131 g\u00f6steriyor. <\/p>\n
Y\u00fcksek risk grubundaki hastalarda, bevacizumab eklenmesiyle sa\u011fkal\u0131mda olumlu bir e\u011filim yakaland\u0131. Bevacizumabl\u0131 kombine tedavi alan hastalarda medyan genel sa\u011fkal\u0131m (OS) 31,1 ay olarak hesaplan\u0131rken, kemoterapi grubunda 27,4 ay olarak saptand\u0131. Bu fark istatistiksel olarak klasik anlamda anlaml\u0131 olmasa da klinik a\u00e7\u0131dan umut verici bir e\u011filimi i\u015faret etti. Buna kar\u015f\u0131n d\u00fc\u015f\u00fck riskli hastalarda ayn\u0131 fayda g\u00f6r\u00fclmedi; TTNT ve OS a\u00e7\u0131s\u0131ndan anlaml\u0131 farkl\u0131l\u0131k bulunmad\u0131. Bu durum, bevacizumab\u0131n etkinli\u011finin hastalar\u0131n prognoz \u00f6zelliklerine ba\u011fl\u0131 olarak de\u011fi\u015fti\u011fini destekledi. <\/p>\n
Ara\u015ft\u0131rman\u0131n bulgular\u0131, over kanser tedavisinde risk bazl\u0131 hasta se\u00e7iminde bevacizumab\u0131n kullan\u0131m\u0131n\u0131n \u00f6nemli ve gereklili\u011fini ortaya koyuyor. \u00d6zellikle cerrahi sonras\u0131 rezid\u00fcel hastal\u0131k hacmi ve hastal\u0131k evresi gibi prognoz fakt\u00f6rleri, tedavinin ki\u015fiselle\u015ftirilmesinde temel kriter haline geliyor. Bu da, tedavi ba\u015far\u0131s\u0131n\u0131 art\u0131r\u0131rken, maliyet ve yan etki profilini optimize etmeye olanak tan\u0131yor. University of Virginia School of Medicine\u2019den Dr. Linda R. Duska, \u00e7al\u0131\u015fman\u0131n lideri olarak, her hastan\u0131n risk profiline g\u00f6re bevacizumab kullan\u0131m\u0131 \u00f6ncesi detayl\u0131 de\u011ferlendirme yap\u0131lmas\u0131n\u0131n \u00f6nemini vurgulad\u0131. <\/p>\n
Molek\u00fcler d\u00fczeyde bevacizumab, t\u00fcm\u00f6r\u00fcn kan damarlar\u0131n\u0131 besleyen VEGF-A sinyal yolunu bloke ederek, t\u00fcm\u00f6r\u00fcn oksijen ve besin ihtiyac\u0131n\u0131 k\u0131s\u0131tlamak suretiyle b\u00fcy\u00fcme ve metastaz\u0131 engeller. Ancak anti-anjiyogenez tedavisinin etkilerinin ge\u00e7ici olmas\u0131 ve t\u00fcm\u00f6r\u00fcn ba\u015fka damar yap\u0131c\u0131 yollar\u0131 aktive etme kapasitesi, t\u00fcm hasta grubunda s\u0131n\u0131rl\u0131 sa\u011fkal\u0131m avantajlar\u0131na neden oluyor. Bu biyolojik karma\u015f\u0131kl\u0131k, VEGF-A inhibisyonuna daha duyarl\u0131 hasta alt gruplar\u0131n\u0131 belirleme gereklili\u011fini peki\u015ftiriyor. <\/p>\n
Ger\u00e7ek d\u00fcnya verilerinde genellikle klinik \u00e7al\u0131\u015fma d\u0131\u015f\u0131 hasta \u00f6zelliklerinin (komorbiditeler, performans durumu, tedavi uyumu) \u00e7e\u015fitlili\u011fi daha y\u00fcksektir. BEV1L \u00e7al\u0131\u015fmas\u0131, bu heterojen \u00e7al\u0131\u015fma ko\u015fullar\u0131nda da klinik deney sonu\u00e7lar\u0131n\u0131n do\u011fruland\u0131\u011f\u0131n\u0131 g\u00f6stererek, bevacizumab\u0131n rol\u00fc ve s\u0131n\u0131rlar\u0131na dair daha g\u00fcvenilir bir klinik tablo sunuyor. Bununla birlikte yan\u0131t\u0131 \u00f6ng\u00f6ren biyobelirte\u00e7lerin tan\u0131mlanmas\u0131 ve direnci a\u00e7\u0131klayan mekanizmalar\u0131n ara\u015ft\u0131r\u0131lmas\u0131 ihtiya\u00e7lar\u0131 devam ediyor. <\/p>\n
Y\u00fcksek riskli hastalarda elde edilen TTNT\u2019deki gecikme, hastalar\u0131n ya\u015fam kalitesi ve sa\u011fl\u0131k kaynaklar\u0131n\u0131n etkin kullan\u0131m\u0131 a\u00e7\u0131s\u0131ndan \u00f6nemli sonu\u00e7lar do\u011furabilir. \u0130kinci basamak tedaviye ge\u00e7i\u015fin gecikmesi, daha toksik ve maliyetli tedavilerin ba\u015flang\u0131c\u0131n\u0131n \u00f6telenmesi anlam\u0131na gelerek, hem hastalar hem sa\u011fl\u0131k sistemi i\u00e7in avantaj sa\u011flar. Bu durum, hastal\u0131k kontrol\u00fcn\u00fcn s\u00fcrd\u00fcr\u00fclebilmesi ve semptom y\u00f6netimi i\u00e7in geni\u015fletilmi\u015f bir zaman dilimi sunar. <\/p>\n
\u00c7al\u0131\u015fma ayn\u0131 zamanda elektronik sa\u011fl\u0131k kay\u0131tlar\u0131 veritabanlar\u0131n\u0131n klinik ara\u015ft\u0131rmalarda ger\u00e7ek d\u00fcnya verilerinin toplanmas\u0131 ve analizinde ne denli kritik bir kaynak oldu\u011funu bir kez daha g\u00f6stermi\u015ftir. Uzun vadeli tedavi desenleri, hasta \u00f6zellikleri ve sonu\u00e7lar\u0131na ait \u00e7ok boyutlu veriler, randomize kontroll\u00fc deneyler ile tamamlay\u0131c\u0131 bi\u00e7imde klinik prati\u011fe rehberlik etmektedir. Bu t\u00fcr veri tabanlar\u0131, onkoloji tedavi algoritmalar\u0131n\u0131n optimize edilmesi a\u00e7\u0131s\u0131ndan giderek daha fazla \u00f6nem kazanmaktad\u0131r. <\/p>\n
Sonu\u00e7 olarak, kontroll\u00fc klinik deneyler ve bu b\u00fcy\u00fck \u00f6l\u00e7ekli ger\u00e7ek d\u00fcnya \u00e7al\u0131\u015fmas\u0131n\u0131n verileri bir araya geldi\u011finde, bevacizumab\u0131n over kanserinde ilk basamak kemoterapiye eklenmesinin faydas\u0131n\u0131n s\u0131n\u0131rl\u0131 ve b\u00fcy\u00fck \u00f6l\u00e7\u00fcde y\u00fcksek riskli hasta se\u00e7kisiyle ili\u015fkili oldu\u011fu netlik kazanm\u0131\u015ft\u0131r. Bu t\u0131bbi ger\u00e7ek, tedavi stratejilerinin risk odakl\u0131, ki\u015fiye \u00f6zg\u00fc planlanmas\u0131n\u0131n tarifi yap\u0131lm\u0131\u015f ve hastalara gereksiz y\u00fcklerin azalt\u0131lmas\u0131 i\u00e7in yol haritas\u0131 \u00e7izmi\u015ftir. <\/p>\n
Onkoloji sahas\u0131nda ilerleyen d\u00f6nemde molek\u00fcler profilleme ve biyobelirte\u00e7 bazl\u0131 tedavi se\u00e7imi ile bevacizumab benzeri ila\u00e7lar\u0131n kombinasyonlar\u0131n\u0131n etkilerinin ara\u015ft\u0131r\u0131lmas\u0131 b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yacakt\u0131r. Tedaviye yan\u0131t veren hasta gruplar\u0131n\u0131n daha iyi belirlenmesi, diren\u00e7 olu\u015fumunun engellenmesi ve tedavi optimizasyonu y\u00f6n\u00fcnde tasarlanacak prospektif \u00e7al\u0131\u015fmalar\u0131n \u00f6nemi giderek artmaktad\u0131r. Bu ara\u015ft\u0131rma, ki\u015fiselle\u015ftirilmi\u015f onkoloji alan\u0131nda yeni ufuklar\u0131 i\u015faret eden bir mihenk ta\u015f\u0131 olmu\u015ftur. <\/p>\n
Ara\u015ft\u0131rma Konusu<\/strong>: Makale Ba\u015fl\u0131\u011f\u0131<\/strong>: Haberin Yay\u0131n Tarihi<\/strong>: Web References<\/strong>: Doi Referans<\/strong>: Anahtar Kelimeler<\/strong>: \u0130leri evre over kanserinde birinci basamak kemoterapiye bevacizumab eklenmesinin ger\u00e7ek d\u00fcnya sonu\u00e7lar\u0131n\u0131 inceleyen kapsaml\u0131 elektronik sa\u011fl\u0131k kay\u0131tlar\u0131 veritaban\u0131na dayanan yeni bir ara\u015ft\u0131rma, bu tedavinin faydalar\u0131n\u0131n s\u0131n\u0131rl\u0131 oldu\u011funu ve \u00f6zellikle y\u00fcksek riskli hasta alt gruplar\u0131yla s\u0131n\u0131rl\u0131 kald\u0131\u011f\u0131n\u0131 ortaya koydu. American Cancer Society\u2019nin sayg\u0131n dergisi CANCER\u2019da yay\u0131mlanan \u00e7al\u0131\u015fmada, bevacizumab\u0131n eklenmesinin sa\u011fkal\u0131mda genel hastalar aras\u0131nda anlaml\u0131 bir uzama…<\/p>\n","protected":false},"author":1,"featured_media":5658,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_wpan_schema_json_ld":"","_wpan_ai_seo_metadata":"","_wpan_ai_seo_status":"","_wpan_ai_seo_policy":"","_wpan_ai_seo_faq_block":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[28],"tags":[7479,7483,7480,7482,7481],"tmauthors":[],"class_list":{"0":"post-5657","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-kanser","8":"tag-bevacizumab-ile-over-kanseri-tedavi-sonuclari","9":"tag-gercek-dunya-verileri-ile-over-kanseri-tedavi-analizi","10":"tag-ileri-evre-over-kanserinde-bevacizumab-etkinligi","11":"tag-over-kanserinde-kemoterapiye-bevacizumab-eklenmesi","12":"tag-yuksek-riskli-over-kanseri-hastalarinda-tedavi-stratejileri"},"jetpack_featured_media_url":"https:\/\/haber360.com\/wp-content\/uploads\/2025\/05\/Bevasizumabin-Over-Kanserindeki-Klinik-ve-Gercek-Sonuclari-1747078165.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/comments?post=5657"}],"version-history":[{"count":0,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/posts\/5657\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media\/5658"}],"wp:attachment":[{"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/media?parent=5657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/categories?post=5657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tags?post=5657"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/haber360.com\/index.php\/wp-json\/wp\/v2\/tmauthors?post=5657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nGer\u00e7ek d\u00fcnya verileriyle ileri evre over kanseri hastalar\u0131nda birinci basamak kemoterapiye bevacizumab eklenmesinin etkinli\u011finin de\u011ferlendirilmesi. <\/p>\n
\n\u201cThe BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?\u201d <\/p>\n
\n12-May-2025 <\/p>\n
\nhttps:\/\/www.wiley.com\/
\nhttps:\/\/acsjournals.onlinelibrary.wiley.com\/journal\/10970142 <\/p>\n
\nDuska, L. R., Lim, J., Calder\u00f3n Boyle, T. A., et al. (2025). CANCER. DOI: 10.1002\/cncr.35821. <\/p>\n
\nOvarian cancer, Clinical trials, Drug studies, Chemotherapy, Cancer medication, Monoclonal antibodies, angiogenesis inhibition in cancer, bevacizumab ovarian cancer treatment, clinical trial outcomes, real-world evidence, electronic health records investigation, first-line chemotherapy efficacy, high-risk patient subgroups, monoclonal antibody therapy, overall survival analysis, retrospective study on bevacizumab, survival advantage in advanced ovarian cancer, therapeutic value of bevacizumab<\/p>\n","protected":false},"excerpt":{"rendered":"